Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Neuro-Oncology
Erschienen in: Journal of Neuro-Oncology 3/2014

01.07.2014 | TOPIC REVIEW & CLINICAL GUIDELINES

The role of imaging in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

verfasst von: Timothy Charles Ryken, Nafi Aygun, Johnathan Morris, Marin Schweizer, Rajeshwari Nair, Cassandra Spracklen, Steven N. Kalkanis, Jeffrey J. Olson

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Question

Which imaging techniques most accurately differentiate true tumor progression from pseudo-progression or treatment related changes in patients with previously diagnosed glioblastoma?

Target population

These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process.

Recommendations

Level II

Magnetic resonance imaging with and without gadolinium enhancement is recommended as the imaging surveillance method to detect the progression of previously diagnosed glioblastoma.

Level II

Magnetic resonance spectroscopy is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.

Level III

The routine use of positron emission tomography to identify progression of glioblastoma is not recommended.

Level III

Single-photon emission computed tomography imaging is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.
Literatur
1.
Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8):2163–2172PubMedCentralPubMedCrossRef
2.
Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212PubMedCrossRef
3.
Easaw JC, Mason WP, Perry J et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Current Oncol 18(3):e126–e136CrossRef
4.
Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC (2009) Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 93(1):1–23PubMedCrossRef
5.
Olson JJ, Ryken T (2008) Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 89(3):255–258PubMedCrossRef
6.
Brandes AA, Tosoni A, Spagnolli F et al (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10(3):361–367PubMedCentralPubMedCrossRef
7.
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461PubMedCrossRef
8.
Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633–638PubMedCrossRef
9.
Sanghera P, Perry J, Sahgal A et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37(1):36–42PubMed
10.
Hollingworth W, Medina LS, Lenkinski RE et al (2006) A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 27(7):1404–1411PubMed
11.
Matz PG, Anderson PA, Kaiser MG et al (2009) Introduction and methodology: guidelines for the surgical management of cervical degenerative disease. J Neurosurg Spine 11(2):101–103PubMedCrossRef
12.
Mukundan S, Holder C, Olson JJ (2008) Neuroradiological assessment of newly diagnosed glioblastoma. J Neurooncol 89(3):259–269PubMedCrossRef
13.
Dean BL, Drayer BP, Bird CR et al (1990) Gliomas: classification with MR imaging. Radiology 174(2):411–415PubMed
14.
Johnson PC, Hunt SJ, Drayer BP (1989) Human cerebral gliomas: correlation of postmortem MR imaging and neuropathologic findings. Radiology 170(1 Pt 1):211–217PubMed
15.
Ballman KV, Buckner JC, Brown PD et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9(1):29–38PubMedCentralPubMedCrossRef
16.
Lamborn KR, Yung WK, Chang SM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10(2):162–170PubMedCentralPubMedCrossRef
17.
18.
19.
Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197PubMedCrossRef
20.
Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 94(1):97–101PubMedCrossRef
21.
Batchelor TT, Duda DG, di Tomaso E et al (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817–2823PubMedCentralPubMedCrossRef
22.
Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729PubMedCrossRef
23.
Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740PubMedCrossRef
24.
Kreisl TN, Kim L, Moore K et al (2009) A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res Off J Am Assoc Cancer Res 15(10):3617–3623CrossRef
25.
Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745PubMedCentralPubMedCrossRef
26.
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed
27.
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972PubMedCrossRef
28.
Wen PY, Norden AD, Drappatz J, Quant E (2010) Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 12(1):68–75PubMedCrossRef
29.
van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria. J Clin Oncol 27(18):2905–2908PubMedCentralPubMedCrossRef
30.
Agbi CB, Bernstein M, Laperriere N, Leung P, Lumley M (1992) Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys 23(2):321–326PubMedCrossRef
31.
Aiken AH, Chang SM, Larson D, Butowski N, Cha S (2008) Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 72(5):1340–1346PubMedCrossRef
32.
Curnes JT, Laster DW, Ball MR, Moody DM, Witcofski RL (1986) MRI of radiation injury to the brain. AJR. Am J Roentgenol 147(1):119–124PubMedCrossRef
33.
Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH (1986) Brain radiation lesions: MR imaging. Radiology 158(1):149–155PubMed
34.
Kleinberg L, Yoon G, Weingart JD et al (2009) Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence. Int J Radiat Oncol Biol Phys 75(5):1385–1391PubMedCrossRef
35.
Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217(2):377–384PubMedCrossRef
36.
Sneed PK, Gutin PH, Larson DA et al (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29(4):719–727PubMedCrossRef
37.
Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2):405–410PubMedCrossRef
38.
Valery CA, Marro B, Boyer O et al (2001) Extent of tumor-brain interface: a new tool to predict evolution of malignant gliomas. J Neurosurg 94(3):433–436PubMedCrossRef
39.
Al Sayyari A, Buckley R, McHenery C, Pannek K, Coulthard A, Rose S (2010) Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy. AJNR Am J Neuroradiol 31(6):1049–1054PubMedCrossRef
40.
Barajas RF Jr, Chang JS, Segal MR et al (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253(2):486–496PubMedCentralPubMedCrossRef
41.
Hu LS, Eschbacher JM, Heiserman JE et al (2012) Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol 14(7):919–930PubMedCentralPubMedCrossRef
42.
Ringelstein A, Turowski B, Gizewski ER et al (2010) Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 182(10):868–872PubMedCrossRef
43.
Sawlani RN, Raizer J, Horowitz SW et al (2010) Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging—pilot study. Radiology 255(2):622–628PubMedCentralPubMedCrossRef
44.
Sorensen AG, Batchelor TT, Zhang WT et al (2009) A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13):5296–5300PubMedCentralPubMedCrossRef
45.
Stenberg L, Englund E, Wirestam R, Siesjo P, Salford LG, Larsson EM (2006) Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme. Acta Radiol (Stockholm, Sweden: 1987) 47(8):852–861
46.
Vrabec M, Van Cauter S, Himmelreich U et al (2011) MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology 53(10):721–731PubMedCrossRef
47.
Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP (2011) A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. Br J Radiol 13(12):1349–1363
48.
Rollin N, Guyotat J, Streichenberger N, Honnorat J, Tran Minh VA, Cotton F (2006) Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 48(3):150–159PubMedCrossRef
49.
Sundgren PC, Fan X, Weybright P et al (2006) Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 24(9):1131–1142PubMedCrossRef
50.
Zeng QS, Li CF, Liu H, Zhen JH, Feng DC (2007) Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 68(1):151–158PubMedCrossRef
51.
Ando K, Ishikura R, Nagami Y et al (2004) Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions. Nihon Igaku Hoshasen Gakkai Zasshi 64(3):121–126PubMed
52.
Chuang CF, Chan AA, Larson D et al (2007) Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas. Technol Cancer Res Treat 6(5):375–382PubMed
53.
Lichy MP, Henze M, Plathow C, Bachert P, Kauczor HU, Schlemmer HP (2004) Metabolic imaging to follow stereotactic radiation of gliomas—the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 176(8):1114–1121PubMedCrossRef
54.
Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR (2010) Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 52(4):297–306PubMedCrossRef
55.
Plotkin M, Gneveckow U, Meier-Hauff K et al (2006) 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperth 22(4):319–325CrossRef
56.
Rabinov JD, Lee PL, Barker FG et al (2002) In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 225(3):871–879PubMedCrossRef
57.
Srinivasan R, Phillips JJ, Vandenberg SR et al (2010) Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol 12(11):1152–1161PubMedCentralPubMedCrossRef
58.
Traber F, Block W, Flacke S et al (2002) 1H-MR spectroscopy of brain tumors in the course of radiation therapy: use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 174(1):33–42PubMedCrossRef
59.
Wald LL, Nelson SJ, Day MR et al (1997) Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 87(4):525–534PubMedCrossRef
60.
Weybright P, Sundgren PC, Maly P et al (2005) Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 185(6):1471–1476PubMedCrossRef
61.
Zeng QS, Li CF, Zhang K, Liu H, Kang XS, Zhen JH (2007) Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 84(1):63–69PubMedCrossRef
62.
Lichy MP, Bachert P, Henze M, Lichy CM, Debus J, Schlemmer HP (2004) Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 46(2):126–129PubMedCrossRef
63.
Plotkin M, Eisenacher J, Bruhn H et al (2004) 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neurooncol 70(1):49–58PubMedCrossRef
64.
Petrirena GJ, Goldman S, Delattre JY (2011) Advances in PET imaging of brain tumors: a referring physician’s perspective. Curr Opin Oncol 23(6):617–623PubMedCrossRef
65.
Enslow MS, Zollinger LV, Morton KA et al (2012) Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 37(9):854–861PubMedCentralPubMedCrossRef
66.
Potzi C, Becherer A, Marosi C et al (2007) [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol 84(3):305–314PubMedCrossRef
67.
Tripathi M, Sharma R, Varshney R et al (2012) Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 37(2):158–163PubMedCrossRef
68.
Chin HW, Fruin AH, Bertoni JM et al (1991) Application of positron emission tomography to neurological oncology. Neb Med J 76(3):70–73
69.
Galldiks N, Kracht LW, Burghaus L et al (2010) Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging 9(1):40–46PubMed
70.
Eary JF, Mankoff DA, Spence AM et al (1999) 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 59(3):615–621PubMed
71.
Schnell O, Krebs B, Carlsen J et al (2009) Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] galacto-RGD positron emission tomography. Neuro Oncol 11(6):861–870PubMedCentralPubMedCrossRef
72.
Ishizu K, Sadato N, Yonekura Y et al (1994) Enhanced detection of brain tumors by [18F]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr 18(1):12–15PubMedCrossRef
73.
Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE (2006) 3’-Deoxy-3’-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol 8(6):340–347PubMedCrossRef
74.
Vos MJ, Tony BN, Hoekstra OS, Postma TJ, Heimans JJ, Hooft L (2007) Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in the detection of recurrent glioma. Nucl Med Commun 28(6):431–439PubMedCrossRef
75.
Carvalho PA, Schwartz RB, Alexander E 3rd et al (1992) Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 77(4):565–570PubMedCrossRef
76.
Kline JL, Noto RB, Glantz M (1996) Single-photon emission CT in the evaluation of recurrent brain tumor in patients treated with gamma knife radiosurgery or conventional radiation therapy. AJNR Am J Neuroradiol 17(9):1681–1686PubMed
77.
Lorberboym M, Baram J, Feibel M, Hercbergs A, Lieberman L (1995) A prospective evaluation of thallium-201 single photon emission computerized tomography for brain tumor burden. Int J Radiat Oncol Biol Phys 32(1):249–254PubMedCrossRef
78.
Schwartz RB, Carvalho PA, Alexander E 3rd, Loeffler JS, Folkerth R, Holman BL (1991) Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201TI and 99mTc-HMPAO. AJNR Am J Neuroradiol 12(6):1187–1192PubMed
79.
Schwartz RB, Holman BL, Polak JF et al (1998) Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy. J Neurosurg 89(1):60–68PubMedCrossRef
80.
Slizofski WJ, Krishna L, Katsetos CD et al (1994) Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology. Cancer 74(12):3190–3197PubMedCrossRef
81.
Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T (1998) Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir 38(6):342–347 (discussion 347–348)CrossRef
82.
Vos MJ, Berkhof J, Hoekstra OS et al (2012) MRI and thallium-201 SPECT in the prediction of survival in glioma. Neuroradiology 54(6):539–546PubMedCrossRef
83.
Kosuda S, Fujii H, Aoki S et al (1994) Prediction of survival in patients with suspected recurrent cerebral tumors by quantitative thallium-201 single photon emission computed tomography. Int J Radiat Oncol Biol Phys 30(5):1201–1206PubMedCrossRef
84.
Namba H, Togawa T, Yui N et al (1996) The effect of steroid on thallium-201 uptake by malignant gliomas. Eur J Nucl Med 23(8):991–992PubMedCrossRef
85.
Vertosick FT Jr, Selker RG, Grossman SJ, Joyce JM (1994) Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme. Neurosurgery 34(3):396–401PubMedCrossRef
86.
Galban CJ, Chenevert TL, Meyer CR et al (2011) Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res Off J Am Assoc Cancer Res 17(14):4751–4760CrossRef
87.
Sanghera P, Rampling R, Haylock B et al (2012) The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin Oncol (Royal College of Radiologists (Great Britain)) 24(3):216–227CrossRef
Metadaten
Titel
The role of imaging in the management of progressive glioblastoma
A systematic review and evidence-based clinical practice guideline
verfasst von
Timothy Charles Ryken
Nafi Aygun
Johnathan Morris
Marin Schweizer
Rajeshwari Nair
Cassandra Spracklen
Steven N. Kalkanis
Jeffrey J. Olson
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1330-0

Weitere Artikel der Ausgabe 3/2014

Journal of Neuro-Oncology 3/2014 Zur Ausgabe

TOPIC REVIEW & CLINICAL GUIDELINES

The role of radiotherapy in the management of progressive glioblastoma

TOPIC REVIEW & CLINICAL GUIDELINES

Introduction, rationale, and methodology

TOPIC REVIEW & CLINICAL GUIDELINES

The role of targeted therapies in the management of progressive glioblastoma

TOPIC REVIEW & CLINICAL GUIDELINES

The role of cytoreductive surgery in the management of progressive glioblastoma

TOPIC REVIEW & CLINICAL GUIDELINES

The role of neuropathology in the management of progressive glioblastoma

Introduction

Glioblastoma at progression: therapy of a challenging problem addressed candidly with evidence-based techniques

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise